Your browser doesn't support javascript.
loading
[Preliminary effects of toripalimab combined with axitinib in the treatment of advanced renal cell carcinoma].
Zhou, L; Xu, H Y; Yan, X Q; Li, S M; Chi, Z H; Si, L; Cui, Z L; Li, J; Wu, X W; Guo, J; Sheng, X N.
Afiliação
  • Zhou L; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Xu HY; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Yan XQ; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Li SM; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Chi ZH; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Si L; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Cui ZL; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Li J; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Wu XW; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Guo J; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Sheng XN; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
Zhonghua Yi Xue Za Zhi ; 102(2): 136-140, 2022 Jan 11.
Article em Zh | MEDLINE | ID: mdl-35012303
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Anticorpos Monoclonais Humanizados / Axitinibe / Neoplasias Renais / Antineoplásicos Tipo de estudo: Observational_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: Zh Revista: Zhonghua Yi Xue Za Zhi Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: China
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Anticorpos Monoclonais Humanizados / Axitinibe / Neoplasias Renais / Antineoplásicos Tipo de estudo: Observational_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: Zh Revista: Zhonghua Yi Xue Za Zhi Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: China